1365-2796/asset/olbannerleft.gif?v=1&s=2c0da92fd7dd29d6387a79c865c2e722951f9b9b)
1365-2796/asset/olbannercenter.gif?v=1&s=e1b4b2f8709bbf2cd315f2b365ae538cedfe9fdf)
1365-2796/asset/olbannerright.gif?v=1&s=99fa1da70758a077581e13cbfc3cd514826924d8)
TREATMENT OF ESSENTIAL HYPERCHOLESTEROLEMIA WITH CLOFIBRATE AND NICOTINIC ACID
Article first published online: 24 APR 2009
DOI: 10.1111/j.0954-6820.1970.tb08073.x
1970 Association for the Publication of the Journal of Internal Medicine
1365-2796/asset/cover.gif?v=1&s=cacbc88a827c8cece634c3d912e9e672c5a697b5 "Acta Medica Scandinavica")
Additional Information
How to Cite
Nordøy, A. and Gjone, E. (1970), TREATMENT OF ESSENTIAL HYPERCHOLESTEROLEMIA WITH CLOFIBRATE AND NICOTINIC ACID. Acta Medica Scandinavica, 188: 487–490. doi: 10.1111/j.0954-6820.1970.tb08073.x
Publication History
- Issue published online: 24 APR 2009
- Article first published online: 24 APR 2009
- Abstract
- References
- Cited By
Abstract. Two groups, each of ten patients, with essential hypercholesterolemia (type II) were treated with alternating clofibrate and nicotinic acid over a period of six months. One group started with three months of clofibrate treatment and the other with three months of nicotinic acid treatment. No dietary changes were made during the test period. All patients responded with a reduction of serum total cholesterol and phospholipids after a three-month period, either with clofibrate or nicotinic acid. At the end of six months the reduction was more pronounced in both groups, with an average reduction of 28% in serum cholesterol. The effect was independent of which drug was given first.